Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q7RTS9
UPID:
DYM_HUMAN
Alternative names:
Dyggve-Melchior-Clausen syndrome protein
Alternative UPACC:
Q7RTS9; A8K5I8; B2RCF9; B4DKI7; Q3ZTS8; Q6P2P5; Q8N2M0; Q9BVE9; Q9NPU7
Background:
Dymeclin, also known as the Dyggve-Melchior-Clausen syndrome protein, plays a crucial role in the correct organization of the Golgi apparatus and is pivotal in bone development. This protein's involvement in such fundamental cellular processes underscores its importance in human physiology.
Therapeutic significance:
Dymeclin is directly associated with Dyggve-Melchior-Clausen syndrome and Smith-McCort dysplasia 1, both rare genetic disorders affecting bone growth and development. Understanding the role of Dymeclin could open doors to potential therapeutic strategies for these conditions, highlighting the importance of targeted research in uncovering novel treatments.